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Abstract 
Objectives: To evaluate breast findings incidentally detected on body MRI.
Methods: A retrospective review of the institutional database identified 1752 body MRI performed between Janu-
ary 2015 and September 2015. MRI of women with breast tissue visible in the field-of-view were reviewed for breast 
findings. Breast findings were classified with the breast imaging reporting and data system (BI-RADS) lexicon. The 
standard statistic, costs of additional work-up, and the clinical relevance were used to describe breast findings, and we 
calculated 95 % exact confidence intervals (CIs).
Results: 440 body MRI of 440 women (mean age: 57 ± 20 years) included breast tissue in the field-of-view. A total of 
41 breast findings were identified in 41 patients. Breast findings were classified BI-RADS 2 N = 25, BI-RADS 3 N = 13, 
BI-RADS 4 N = 3. A total of 3.6 % [95 % CI 1.6 %, 5.6 %] women with breast tissue visible on MRI had a recommenda-
tion for further imaging work-up for a breast finding. The 18.7 % (3 of 16) of these patients had a clinically important 
finding (breast cancer). Further imaging evaluation increased costs of €108.3 per patient with a breast finding.
Conclusions: Clinically important breast findings could be detected on body MRI in up to 0.7 % (3 of 440) of women.
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Background
Body magnetic resonance imaging (MRI) is a highly sen-
sitive imaging method to assess morphological struc-
tures and the presence of a lesion (Schmidt et al. 2013). 
Since there has been an increased use of MRI in clinical 
practice, an increased number of incidental findings are 
expected (Chernyak et al. 2015; Wagner and Aron 2012; 
Sebastian et al. 2013; Heller et al. 2013; Khosa et al. 2013; 
Patel et al. 2013). Indeed, incidental findings are increas-
ingly common, and the American College of Radiology 
developed guidelines for management of incidental find-
ings detected during abdominal and pelvic MRI or com-
puted tomography (CT) (Sebastian et  al. 2013; Heller 
et al. 2013; Khosa et al. 2013; Patel et al. 2013). In addi-
tion, several studies evaluated incidental findings outside 
the region-of-interest during MRI of the heart, breast 
and spine, using an expanded field-of-view (FOV) (Wyt-
tenbach et  al. 2012; Bazzocchi et  al. 2012; Dewey et  al. 
2007; Maxwell et al. 2015). Regarding MRI of the abdo-
men and the chest (body MRI), different field-of-views 
are used, based on the clinical suspicious and the specific 
region-of-interest to be evaluated. In the most frequent 
clinical indications of body MRI, the anteroposterior size 
of FOV is approximately 30 centimetres (Erturk et  al. 
2009; Chang et al. 2008; Lee et al. 2014). Therefore, some 
breast tissue could be included in body MR examina-
tions, and consequently, some incidental breast findings 
could be potentially detected. In literature, incidental 
breast findings have been evaluated and described on 
CT and (18) F-fluorodeoxyglucose (FDG) positron emis-
sion tomography (PET)–CT (Bach et al. 2013; Monzawa 
et  al. 2013; Benveniste et  al. 2015). In a population of 
patients with known non-mammary malignancies, 6 % of 
incidental breast lesions detected on FDG PET/CT were 
primary breast cancer (Benveniste et  al. 2015). Several 
studies evaluated potentially relevant incidental findings 
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on MRI, including breast findings, but all of these studies 
dealt with whole-body MRI and not with more tailored 
MR examinations (Cieszanowski et  al. 2014; Tarnoki 
et  al. 2015). To the best of our knowledge, there are no 
studies in literature dealing with breast findings detected 
on body (abdominal and chest) MRI. Therefore, the aim 
of our study was to evaluate breast findings incidentally 
detected on body MRI, recommendations for further 
imaging work-up, and the clinical relevance and health 
care costs.
Methods
This study was notified to the Institutional Review Board, 
and the requirement for informed consent was waived. 
Our Centre is a Tertiary Centre with more than 6.000 
MRI examinations performed in a year and more than 
2.000 are body MRI examinations. Figure  1 shows the 
flow-chart of the study.
A retrospective query of our body MRI database was 
performed by seven radiologists in March 2016. The 
seven radiologists (B.B., G.S., F.N., M.P., L.G., S.B., L.S.) 
had more than 3 years of experience in body and breast 
imaging. The retrospective query included the review 
of the images of body MRI with breast tissue visible on 
abdominal and chest MRI. The query was done between 
January 2015 and September 2015. At least 6-months fol-
low-up period of the lesions classified as benign was war-
ranted. For patients who underwent more than one body 
MRI during the time interval, we recorded each MRI as 
a separate event. Dedicated breast, musculoskeletal and 
MR neuro imaging examinations were excluded from the 
investigation.
A total of 1752 body MRI examinations were reviewed. 
MRI examinations of male patients and with no breast 
tissue visible were excluded. Breast findings were evalu-
ated on the remaining body MRI in female patients with 
breast tissue visible.
For each body MRI examination with breast tissue vis-
ible, the percentage of breast tissue visible was recorded 
and visually estimated as more or less than 50  % of the 
total breast volume. In addition, patient age, mag-
netic field where the MRI was performed and MRI type 
(abdominal or chest) were recorded. In particular, the 
FOV size and the type of the contrast agent used and the 
presence or absence of diffusion-weighted images were 
recorded.
MRI technique and image interpretation
Abdominal and chest MRI were performed with the 
patient in a supine position by using a 1.5 T (Magnetom 
Avanto, Siemens, Germany) or a 3.0 T (GE Signa HDx 
3.0T, General Electric Medical Systems, Milwaukee, WI, 
USA) scanners with dedicated phased-array coil usually 
in combination with table-embedded spine coils. We per-
formed abdominal and chest MRI following Institutional 
guidelines. Each examination was tailored to the patient 
clinical feature (body mass index) and the body region to 
be studied.
Image interpretation
Two breast radiologists (A.T., M.C.), with more than 5 
and 10  years of experience in breast MRI respectively, 
reviewed the MR images with detected breast findings 
and recorded the characteristic of the breast findings 
following the breast imaging reporting and data system 
(BI-RADS) MRI lexicon (American college of radiology 
breast imaging reporting and data system (BI-RADS) 
Atlas 2013). The two radiologists were blinded to clini-
cal outcomes and previous breast imaging evaluation. 
For any patient who had more than one breast finding, 
each finding was included in the study. A single breast 
finding was considered for any patient with more than 
one simple breast cyst. For each body MRI with a breast 
finding, one radiologist (B.B.) reviewed the MRI report to 
evaluate any recommendations for additional work-up. 
The same radiologist assessed in the electronic medical 
record the availability of clinical follow-up and/or previ-
ous MRI examinations for comparison, or results of any 
additional imaging and histopathological work-up at our 
Institution for at least 6  months after the body MRI to 
evaluate the clinical relevance of breast finding and to Fig. 1 Flow-chart of the study design
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follow-up the lesion classified as benign. Any breast find-
ings initially assigned to BI-RADS category 3 but previ-
ously evaluated and described in the electronic medical 
record was downgraded and assigned to BI-RADS cat-
egory 2, as previously performed in other similar setting 
(Niell et al. 2015).
Cost analysis
The costs of further imaging evaluation and procedures 
were calculated on the basis of the reimbursement pro-
posed at our Institution (€120 for standard mammog-
raphy; €120 for breast ultrasonography; €400 for breast 
MRI; €200 for ultrasonography breast core-needle 
biopsy; €200 for ultrasound-guided preoperative lesion 
marking) and were intended as costs theoretically paid by 
patients. All further breast imaging work-up, follow-up 
and procedures performed after body MRI recommenda-
tion was included in the cost analysis.
Statistical analysis
A descriptive analysis was performed among the patient 
population and corresponding MRI characteristic 
included in the study (patient age, percentage of breast 
tissue visible, MR magnetic field, type of MRI (abdomi-
nal or chest), the FOV size, the type of the contrast-
media, number of examinations with diffusion-weighted 
images). We compared the presence of a breast finding 
and subsequent recommendations for further imaging 
and procedures between the groups of patients that per-
formed abdominal and chest MRI, between the groups 
of patients that performed contrast-enhanced MRI and 
non-contrast enhanced MRI using the Fisher’s exact test. 
A p value of less than 0.05 was considered statistically 
significant significance (MedCalc Software bvba. Acacia-
laan 22, Ostend, Belgium) and we calculated 95 % exact 
confidence intervals (CIs). A clinically important finding 
in the breast was considered to be a cancer.
Results
Breast findings
440 body MRI examinations of 440 women (mean age: 
57 ± 20 years) included breast tissue in the field-of-view 
(FOV range in abdominal MRI in millimetres: 340 × 276 
to 400  ×  337; FOV range in chest MRI: 350  ×  295 to 
380  ×  344). Among the 440 body MRI examinations, 
302 body MRI were performed on a 1.5 T scanner and 
138 body MRI were performed on a 3.0 T scanner. In 201 
patients (45.7 %), MRI showed more than 50 % of breast 
tissue, whereas in 239 patients (54.3 %) showed less than 
50 % of breast tissue. MRI indications were: N = 216 liver 
imaging, N = 68 pancreatic imaging, N = 32 renal imag-
ing, N =  17 adrenal imaging and N =  14 MR enterog-
raphy; N  =  66 mediastinum and N  =  27 thoracic wall 
imaging. In 286 patients, body MRI was performed 
with intravenous contrast material injection; in 145 
patients was performed gadoxetic acid enhanced MRI, 
in 109 patients was performed gadobenate dimeglumine-
enhanced and in 32 patients gadoteridolo enhanced MRI.
Breast findings were identified in 41 of 440 patients 
(9.3  %). All these patients had a single breast finding. 
Table 1 shows body MRI with breast finding by BI-RADS 
category. Of the 41 patients with breast findings detected 
at body MRI, 25 patients (59.5  %) were categorized as 
BI-RADS 2; among these, three patients (12.0  %) were 
downgraded from an initial BI-RADS 3 or 4 by previ-
ous imaging work-up or review of the electronic medical 
record. Among the 25 findings classified as BI-RADS 2, 
the most common included simple breast cysts [88.0  % 
(22 of 25)]; previously known round or oval smoothly 
marginated hypervascular masses with some fat inside 
were the other benign findings [12.0 % (3 of 25)].
A total of 16 breast incidental findings were categorized 
as BI-RADS 3 and 4, and the most common imaging 
findings included breast enhancing masses detected after 
contrast injection [87.5 % (14 of 16)]. The others imaging 
finding of BI-RADS 3 and 4 are described in Table 1.
Among the 41 patients with breast findings, 34 patients 
[82.9  % (34 of 41)] had breast finding identified dur-
ing abdominal MRI and seven patients [17.1 % (7 of 41)] 
had breast finding identified during chest MRI (Table 2). 
Examples of patients with breast findings are shown in 
Figs. 2, 3 and 4.
Of the 347 patients who underwent abdominal MRI, 34 
patients (9.8 %) had a breast finding and of the 93 patients 
who underwent chest MRI, seven patients (7.5 %) had a 
breast finding (p = 0.69).
Further imaging recommendation and clinical relevance
Of the 440 body MRI examinations, 16 patients (3.6  % 
[95  % CI 1.6  %, 5.6  %]) had a recommendation for an 
additional imaging to be performed for further evalua-
tion of a breast finding. Of these 16 patients, 13 patients 
(81 %) were evaluated as BI-RADS category 3 and three 
patients (19  %) were evaluated as BI-RADS 4. Patient 
with BI-RADS 2 findings did no receive recommenda-
tion for additional imaging. Only one patient with chest 
MRI received additional imaging recommendation for a 
BI-RADS 3 finding.
Of the 347 patients who underwent abdominal MRI, 
15 patients (4.3 %) received additional recommendation 
for further imaging and procedures. Of the 93 patients 
who underwent chest MRI, one patient (1.1 %) received 
additional recommendation for further imaging for a BI-
RADS 3 breast finding (p = 0.212).
Patients with contrast-enhanced MRI were significantly 
more likely to have a recommendation for additional 
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imaging evaluation compared with patients undergoing 
non contrast-enhanced MRI (non-enhanced MRI, one 
patients; contrast-enhanced MRI, 15 patients; p = 0.015).
All patients who underwent contrast-enhanced MRI 
were, on average, aged 63.5 years (age range, 19–84 years) 
compared with 59.9 years (age range, 26–88 years) for all 
patients with non contrast-enhanced MRI (p = 0.0063).
All patients who underwent abdominal MRI were, on 
average, aged 61.8  years (age range, 19–86  years) com-
pared with 51.2  years (age range, 23–88  years) for all 
patients with chest MRI (p < 0.0001).
Overall, 3.6 % (16 of 440) of female patients with breast 
tissue on body MRI received a recommended additional 
imaging examinations for further evaluation of a proba-
bly benign (BI-RADS 3) or suspicious (BI-RADS 4) breast 
finding by using body MRI. Of the 14 patients [34.1 % (14 
of 41)] with breast finding who underwent the recom-
mended additional imaging on the basis of the body MRI 
findings, 11 patients (78.6 %) were BI-RADS 3 and three 
patients (21.4 %) were BI-RADS 4. Two patients [12.5 % 
(2 of 16)] with BI-RADS 3 were lost at follow-up and 
did not undergo the additional imaging recommended. 
No additional imaging was recommended for incidental 
breast findings categorized as BI-RADS 2.
Clinical relevance of breast incidental finding was 
available for 14 patients (follow-up interval range, 
6–14  months). After undergoing additional imaging 
examinations, three patients [21.4 % (3 of 14)] had a clini-
cally important finding. Two patients had a previously 
unknown invasive breast cancer (invasive ductal car-
cinoma) and one patient had a previously known inva-
sive breast cancer (invasive ductal carcinoma) (Table 3). 
Therefore, 18.7 % (3 of 16) of women undergoing further 
imaging work-up because of recommendation of breast 
incidental finding with body MRI had a clinically impor-
tant finding in the breast.
Three of 440 patients (0.7 %) had a clinically important 
finding identified with body MRI, and these included two 
patients who had previously unknown invasive breast 
cancer.
Table 1 Body MRI findings classified using BI-RADS category with corresponding MRI characteristics
The MRI characteristics represent the imaging characteristics of the incidental breast finding detected on body MRI examinations included in the study
BI-RADS category (0–4) Number of patient with  
breast incidental findings
Breast incidental  
finding (%)
MRI characteristic
BI-RADS 2 + 3+4 41 100
BI-RADS 2 25 59.5
22 88.0 Rounded lesion hyperintense on 
T2-weighted or STIR sequences
3 12.0 Rounded/oval circumscribed mass 
previously described or evaluated
BI-RADS 3 13 30.9
8 61.5 Rounded/oval circumscribed mass not 
previously described or evaluated
4 30.8 Oval mass
1 7.7 T2-weighted or STIR hyperintense 
irregular lesion
BI-RADS 4 3 7.1
2 66.7 Suspicious enhancing mass
1 33.3 Architectural distortion
Table 2 Breast incidental finding in abdominal and chest MRI examinations














Total 5 2 7 (7.5 %) 19 15 34 (9.8 %)
BI-RADS 2 4 2 6 (6.4 %) 4 14 18 (5.2 %)
BI-RADS 3 1 Nf 1 (1.1 %) 12 Nf 12 (3.5 %)
BI-RADS 4 Nf Nf Nf 2 1 3 (0.9 %)
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One patient with a clinically important finding had an 
indication for liver MRI. One patient had an indication 
for pancreatic imaging and the other patient had an indi-
cation for MR cholangiography. One of the three patients 
with a malignant breast lesion had a previous history of 
breast cancer. The remaining two patients had no previ-
ous history of malignancies (Table 3).
Cost of further imaging and procedures
Of the 16 patients with recommendations for addi-
tional imaging, four patients had one additional imag-
ing study recommended, and four patients had two 
additional imaging studies recommended, one patient 
had three additional imaging recommendation, five 
patients had one additional imaging and one proce-
dures recommendation, and two patient had two addi-
tional imaging and two procedures recommendations, 
which totalled 33 additional imaging studies and pro-
cedures that were recommended (Table 4). Enhancing 
mass accounted for 94  % (31 of 33) of these recom-
mendations, including 19 of the 21 recommendations 
for breast ultrasonographic imaging. Of the imaging 
studies that were performed, ultrasound examinations 
were the majority [61 % (19 of 31)] of additional imag-
ing examinations recommended for diagnosis of newly 
identified breast findings.
Subsequent imaging studies and additional costs 
resulted are shown in Table 4.
The total costs for all subsequent imaging studies and 
procedures performed as a result of a body MRI recom-
mendation for additional imaging evaluation and pro-
cedures was €4440. The entire procedures constituted 
the 9 % (€400 of €4440) of the additional costs (Table 4). 
The 2015 costs at our Institution of contrast-enhanced 
abdominal or chest MRI examination is €450, non con-
trast-enhanced is €350. Therefore, for each of the 440 
body MRI examinations included in this study an average 
additional cost of €10.1 was attributable to the additional 
imaging recommended.
Fig. 2 Examples of breast findings by BI-RADS category. A 49-year-
woman underwent abdominal MRI for liver evaluation. Three-
dimensional dynamic axial volumetric interpolated breath-hold 
examination image after intravenous power injection of 0.025 mmol/
kg of gadoxetic acid (Primovist) at 60 s. Less than 50 % of the breast 
tissue was visible at abdominal MRI. An oval nodule (white circle) 
was found in the inner quadrant of the right breast (20 mm). The 
breast finding was first categorized as BI-RADS RM 3. After electronic 
medical record review this finding was downgraded as BI-RADS RM 
2 (known fibrolipoma). In the upper right corner is highlighted the 
breast findings (white arrow)
Fig. 3 Examples of breast incidental findings by BI-RADS category. 
a A 75-year-woman (Patient 1 in Table 3) underwent MR cholangio-
pancreatography. More than 50 % of the breast tissue was visible 
at abdominal MRI. A suspicious architectural distortion (white circle) 
was found in the outer quadrants of the left breast (BI-RADS RM 4). 
In the box is highlighted the breast findings. b Left full-filed digital 
mammography shows an area of architectural distortion (white arrow) 
in the outer quadrants. c Corresponding US image shows a mass 
with indistinct borders in the left breast at 2 o’clock position (15 mm 
diameter). The US-guided core needle biopsy confirmed a B5b lesion 
(invasive ductal carcinoma)
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Sub-analyses of cost were performed for the 16 of 
41 body MRI examinations with breast findings that 
resulted in recommendations for additional imaging 
evaluation. The 2015 costs at our Institution of contrast-
enhanced abdominal or chest MRI examination is €450, 
non contrast-enhanced is €350. Therefore, for each of the 
41 body MRI with incidental breast finding performed in 
this study, an average additional cost of €108.3 was attrib-
utable to the additional imaging recommended.
Discussion
Breast cancer is the most frequent cancer in women and 
is the leading cause of cancer-related deaths of European 
women (Senkus et al. 2015; Sardanelli et al. 2010; Mann 
et  al. 2015). Breast MRI is a highly sensitive imaging 
method for breast cancer detection (Senkus et  al. 2015; 
Sardanelli et  al. 2010; Mann et  al. 2015; Morrow et  al. 
2011). For breast cancer screening, abbreviated and non-
standard MRI protocols have been evaluated (Kuhl et al. 
2014; Mango et al. 2015; Carbonaro et al. 2012).
In clinical practice, a significant amount of breast tis-
sue is commonly visible during body MRI. Therefore, 
given the high sensitivity of MRI, there could be some 
breast findings visible in the field-of-view. In this study, 
we aimed to assess breast findings in women undergoing 
body MRI. To the best of our knowledge, this is the first 
study assessing the presence of breast lesions inciden-
tally detected on abdominal and chest MRI. We found 
that, among female patients undergoing body MRI, at 
least 3.6  % had a recommendation for additional imag-
ing examinations and procedures due to an incidental 
breast finding, and 0.7  % had a clinically relevant inci-
dental breast finding. Notably, we found three invasive 
breast cancers (invasive ductal carcinoma). One patient 
undergoing non contrast-enhanced abdominal MRI had 
an incidental breast finding that received recommenda-
tion for further imaging work-up and this patient was 
revealed to have a breast cancer. The relative high preva-
lence of breast cancer in the group of patients undergo-
ing non contrast-enhanced body MRI compared to the 
group of patients undergoing contrast-enhanced MRI 
could be related to the high intrinsic sensitivity of con-
trast-enhanced body MRI that leads to a higher detec-
tion of breast findings compared to the other group. For 
the same reason, the majority of breast findings detected 
during contrast-enhanced MRI had higher BI-RADS cat-
egory compared to the breast findings detected during 
non-contrast-enhanced MRI. However, this considera-
tion has to be confirmed on larger series. The European 
Society of Breast Imaging (EUSOBI) guidelines acknowl-
edge that breast MRI should be performed routinely with 
contrast agent for diagnostic value (Mann et  al. 2015), 
indeed, we do not believe that non contrast-enhanced 
body MRI could be an accurate imaging modality for 
breast cancer detection. In addition, our results do not 
support the use of body MRI as an additional screening 
modality for breast cancer detection, but highlight the 
possibility to find a breast lesion on body MRI.
Fig. 4 Examples of breast incidental findings by BI-RADS category. 
a A 67-year-woman (Patient 2 in Table 3) underwent abdominal MRI 
for follow-up of a cystic lesion of the head of the pancreas. Three-
dimensional dynamic axial volumetric interpolated breath-hold 
examination image after intravenous power injection of 0.05 mmol/
kg of Gadobenate dimeglumine (Multihance) at 60 s. More than 
50 % of the breast tissue was visible at abdominal MRI. A suspicious 
mass (white circle) was found in the outer quadrants of the right 
breast (BI-RADS RM 4) The US-guided core needle biopsy confirmed 
a B5b lesion (Invasive Ductal Carcinoma). In the upper right corner is 
highlighted the breast findings (white arrow). b A 58-year-woman 
(Patient 3 in Table 3) underwent abdominal MRI for liver evaluation. 
Three-dimensional dynamic axial volumetric interpolated breath-hold 
examination image after intravenous power injection of 0.025 mmol/
kg of gadoxetic acid (Primovist) at 60 s. More than 50 % of the breast 
tissue was visible at abdominal MRI. A suspicious mass (white circle) 
was found in the outer quadrants of the right breast (BI-RADS RM 
4). This patient had a previously known breast cancer in the outer 
quadrants of the right breast, corresponding to the breast finding 
detected on MR images. In the upper right corner is highlighted the 
breast findings (white arrow)
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The prevalence of our findings is consistent with other 
cross-sectional imaging examinations: the detection of 
clinically relevant incidental breast findings varies from 
0.3  % on computed tomography of the body (Monzawa 
et al. 2013), to 6 % on PET-CT (Benveniste et al. 2015). 
Regarding previous studies dealing with incidental breast 
finding on MRI, it has been evaluated the prevalence of 
breast cysts in whole-body MRI, which was 3.5  % for 
patients over the age of 50  years (Cieszanowski et  al. 
2014). However, breast cysts are not clinically relevant. 
A recent report (Bamberg et  al. 2015) shows the design 
of the MRI Study of the German National Cohort with 
a particular mention about incidental findings: a major 
challenge is that the whole-body unenhanced MR proto-
col is different from that used on diagnostic application, 
and, for examples, breast cancer cannot be detected with 
reasonable specificity. Differently from previous studies, 
we reviewed both non-contrast and contrast-enhanced 
abdominal and chest MRI examinations and we were able 
to detect not only breast cysts but more suspicious breast 
incidental findings too.
Regarding the percentage of breast tissue visible in our 
study population during MRI, the majority of patients 
had less than 50 % of breast tissue visible. Therefore, it is 
possible that other breast findings would have been vis-
ible using a larger FOV. Although this study is formally 
retrospective, the MR images review allowed a simile-
prospective reading of all images with a blind assessment 
of the breast tissue that would have not been feasible 
with the review of the MR report alone. This technique 
of reading was very time consuming, but we believe that 
increase and strengthen the results of the study. Regard-
ing costs, we found that additional imaging and proce-
dures for breast findings contributed an increased cost 
of €108.3 for each patient with incidental findings. How-
ever, additional recommendations for breast finding do 
not increase cost significantly per women undergoing 
body MRI with breast tissue visible; indeed, an average 
additional cost of €10.61 was totalled for each patient 
included in the study. We acknowledge that the costs of 
additional recommendation lacks of the costs of the sur-
gical procedures performed for breast cancer therapy, 
underestimating the average additional costs per patient. 
On the contrary, we could not perform a cost-analysis 
about the saving costs for early breast cancer detection.
Our study has other limitations. First, we did not assess 
the correlation between detection of breast finding and 
clinical characteristic and technical parameters. In addi-
tion, we did not evaluate the histological size of the breast 
cancers because the evaluation of the incidence of breast 
cancers during body MRI and its correlation with breast 
cancer characteristics was not the purpose of our study. 
Finally, the study design could have underestimated 
the number of total breast findings due to inclusion of 
patients with percentage of breast tissue visible and not 
the whole breast.
Table 3 Patients with clinical relevant breast finding
Patient Age (years) Previous history 
of cancer












1 75 Previous history 
of breast 
cancer
Abdominal MRI 380 × 261 Not used MR cholangio-
graphy
BI-RADS 4 Invasive ductal 
carcinoma
2 67 No history Abdominal MRI 380 × 380 Gadobenate 
dimeglumine
Pancreatic MRI BI-RADS 4 Invasive ductal 
carcinoma
3 58 No History Abdominal MRI 308 × 380 Gadoxetic acid Liver MRI BI-RADS 4 Invasive ductal 
carcinoma
Table 4 Additional imaging studies and work-up recommended and performed because of breast findings at body MRI 
and associated additional costs
FFDM full-field digital mammography, US ultrasound
◆Two ultrasound examinations were not performed (patients lost at follow-up)






imaging studies and  
work-up recommended
Additional costs for  
imaging studies and  
work-up performed (Euros)
Chest MRI 2 2 240
Abdominal MRI 3 19◆ 7 2 31◆ 4200
Total 3 21◆ 7 2 33◆ 4440 
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Conclusions
In conclusion, at least 3.6 % of women undergoing body 
MRI had a breast incidental finding, and 18.7 % of these 
patients had a clinically relevant incidental breast finding. 
Further imaging work-up and procedures recommended 
did not increase significantly the cost per women under-
going body MRI.
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